1. Fisher B, Redmond C, Brown A, Wickerham D, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1(4):227–241
2. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305(1):1–6
3. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche H, Schwartz MK, Chan DW (eds) Tumor markers: physiology, pathobiology, technology and clinical applications. AACC, Chicago, pp 33–63
4. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72
5. Wittliff J, Pasic R, Bland K (1998) Steroid and peptide hormone receptors: methods, quality control and clinical use. In: Bland KI, Copeland EM III (eds) The breast: comprehensive management of benign and malignant diseases, 2nd edn. WB Saunders Co, Philadelphia, pp 458–498